Current Edition

3

Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018 A pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis …

Continue Reading →